Lumida
/CPRX
⌘K
Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

CPRX
$31.49USD↑+0.00%+0.00 today

MARKET CAP

3.9B

P/E (TTM)

18.1x

FWD P/E

—

DAY RANGE

$31 – $31

52W RANGE

$19
$33

AI Summary

Stalk
Sell NowMedium

CPRX has entered a Stage 3 distribution phase, failing to clear early‐May highs and triggering an active Bullish Exhaustion pattern. Short‐term EMAs have flattened and price is extended above the 9/20/50 EMA zone, increasing pullback risk. Medium‐term bias is bearish under distribution, so execution now on a rejection or rollover near the prior highs and EMAs is recommended to participate in further distribution.

  • ↑2025 revenue up 19.8% YoY to $589M, exceeding guidance.
  • ↑Ferdaps net revenue reached $358.4M (+17%) with ~85% patient retention.
  • ↓FICOMPA revenue forecast drops to $40–45M after patent expiry.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is a leading biopharmaceutical company specializing in the development and commercialization of innovative therapies for rare neurological diseases. Its main products include Ferdaps for Lambert-Eaton Myasthenic Syndrome (LEMS) and Agamri for Duchenne muscular dystrophy (DMD), both targeting conditions with high unmet medical needs. Catalyst operates in a niche market that presents significant growth potential, particularly as it looks to expand its footprint within specialized therapeutic areas, including oncology.

Bull says

  • ↑2025 revenue up 19.8% YoY to $589M, exceeding guidance.
  • ↑Ferdaps net revenue reached $358.4M (+17%) with ~85% patient retention.
  • ↑Agamri launch drove $117.1M in sales (+154% YoY) across DMD centers.
  • ↑$709M cash on hand and $200M buyback bolster financial flexibility.
  • ↑High earnings yield and robust profitability metrics support valuation.
  • ↑Patient ID initiatives in oncology expand long-term growth runway.

Bear says

  • ↓FICOMPA revenue forecast drops to $40–45M after patent expiry.
  • ↓Inflation Reduction Act may raise gross-to-net deductions, hurting margins.
  • ↓Execution risk: Agamri adoption delays or payer shifts could slow sales.
  • ↓Generic entrants could saturate rare disease markets, eroding market share.
  • ↓Negative book-to-price and dividend yield raise valuation and return concerns.
  • ↓Low institutional ownership signals potential underperformance risk.

Investment themes with CPRX

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q4 2024 · Mgmt. Guidance

Updated 07-14-2026bullish

Transcript signals

Bull points

  • We are thrilled with our exceptional performance in 2024, marked by full-year net product revenue of $489.3 million and total revenues of $491.7 million, surpassing the upper end of our 2024 full-year total revenue guidance of $475 to $485 million.
  • Ferdaps' net product revenue for 2024 showed strong 18% growth year-over-year, driven by a steady influx of new patient initiations and a low annual discontinuation rate of under 15 percent, exceeding internal expectations.
  • We are proud of Agamri's successful commercial launch and its growing recognition as a breakthrough treatment for Duchenne muscular dystrophy. Full year 2024 net product revenue reached 46 million, surpassing the revised guidance of 40 million to 45 million.

Bear points

  • The crowded DMD landscape has created a competition for share of voice within these institutions. In addition, we believe there is a cueing effect for patients as they are evaluated for treatment of new therapies, delaying initiation of Agamri for some patients.
  • We anticipate a gradual revenue decline in the second half of 2025 as physicians and patients prioritize clinical civility with a continued decline in 2026 and beyond as payer-driven transitions accelerate.
Read full transcript analysis ›